Citizens Jmp Raises Cytokinetics (NASDAQ:CYTK) Price Target to $88.00

Cytokinetics (NASDAQ:CYTK) had its price objective increased by investment analysts at Citizens Jmp from $78.00 to $88.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has a “market outperform” rating on the biopharmaceutical company’s stock. Citizens Jmp’s price objective suggests a potential upside of 39.04% from the stock’s current price.

Several other analysts have also recently issued reports on CYTK. UBS Group reaffirmed a “neutral” rating and set a $61.00 target price on shares of Cytokinetics in a research report on Monday, December 1st. Stifel Nicolaus upped their price objective on Cytokinetics from $87.00 to $96.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Royal Bank Of Canada raised their price objective on Cytokinetics from $82.00 to $87.00 and gave the company an “outperform” rating in a research report on Tuesday, November 11th. The Goldman Sachs Group set a $95.00 target price on shares of Cytokinetics and gave the stock a “buy” rating in a report on Thursday, December 18th. Finally, Bank of America raised their price target on shares of Cytokinetics from $52.00 to $56.00 and gave the company a “neutral” rating in a report on Thursday, October 2nd. Fifteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Cytokinetics has a consensus rating of “Moderate Buy” and an average price target of $83.61.

Cytokinetics Stock Performance

NASDAQ CYTK opened at $63.29 on Monday. Cytokinetics has a one year low of $29.31 and a one year high of $70.98. The company has a market capitalization of $7.74 billion, a price-to-earnings ratio of -10.06 and a beta of 0.58. The company’s 50-day simple moving average is $62.87 and its two-hundred day simple moving average is $49.10.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, topping the consensus estimate of ($1.59) by $0.05. The business had revenue of $1.94 million during the quarter, compared to analysts’ expectations of $6.05 million. Cytokinetics’s revenue for the quarter was up 318.1% on a year-over-year basis. During the same period in the previous year, the company posted ($1.36) EPS. Equities analysts expect that Cytokinetics will post -5.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Cytokinetics news, EVP Andrew Callos sold 1,042 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $65.96, for a total value of $68,730.32. Following the completion of the sale, the executive vice president owned 50,660 shares of the company’s stock, valued at approximately $3,341,533.60. This trade represents a 2.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Fady Ibraham Malik sold 2,200 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $61.24, for a total value of $134,728.00. Following the sale, the executive vice president owned 138,552 shares in the company, valued at $8,484,924.48. The trade was a 1.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 168,494 shares of company stock valued at $10,811,018 in the last 90 days. 3.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. UMB Bank n.a. grew its holdings in shares of Cytokinetics by 10.6% during the third quarter. UMB Bank n.a. now owns 1,762 shares of the biopharmaceutical company’s stock valued at $97,000 after buying an additional 169 shares during the last quarter. CIBC Private Wealth Group LLC lifted its position in Cytokinetics by 8.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 3,484 shares of the biopharmaceutical company’s stock worth $191,000 after acquiring an additional 261 shares during the period. Fifth Third Bancorp lifted its position in Cytokinetics by 32.3% during the 3rd quarter. Fifth Third Bancorp now owns 1,072 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 262 shares during the period. Teacher Retirement System of Texas grew its stake in Cytokinetics by 1.1% during the 2nd quarter. Teacher Retirement System of Texas now owns 30,514 shares of the biopharmaceutical company’s stock valued at $1,008,000 after purchasing an additional 341 shares during the last quarter. Finally, KLP Kapitalforvaltning AS increased its holdings in shares of Cytokinetics by 1.7% in the second quarter. KLP Kapitalforvaltning AS now owns 24,000 shares of the biopharmaceutical company’s stock valued at $793,000 after purchasing an additional 400 shares during the period.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: FDA approved Myqorzo (aficamten) for obstructive hypertrophic cardiomyopathy, turning Cytokinetics into a commercial-stage cardiology biotech and opening a new revenue runway — a primary driver behind the rally. Article Title
• Positive Sentiment: Multiple brokers lifted price targets and reiterated buy/outperform views (Barclays, Morgan Stanley, BofA, Needham, Citizens/JMP), signaling stronger analyst conviction on commercial prospects and supporting upside. Article Title
• Positive Sentiment: Unusually heavy call-option buying (about 5,619 calls, ~103% above typical daily volume) suggests traders are positioning for additional upside or near-term bullish moves. (Options volume report)
• Positive Sentiment: Analyst commentary highlights practical label advantages for MYQORZO vs. the incumbent (flexible dosing), and management targets substantial market share gains — commentary that supports a multi-quarter adoption story. Article Title
• Neutral Sentiment: Citizens maintained its Market Outperform rating on CYTK, which is supportive but not a new endorsement. Article Title
• Negative Sentiment: Insider selling: director Wendell Wierenga sold 20,000 shares at an average $66.14 (Dec. 22), trimming his stake ~38% — a potential short-term headwind or cautionary signal for some investors. SEC Filing

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.